Nuclear Accumulation of Heat-shock Protein 90 Is Associated with Poor Survival and Metastasis in Patients with Non-small Cell Lung Cancer

被引:2
作者
Su, Jang-Ming [1 ,2 ]
Hsu, Ya-Ying [4 ]
Lin, Pinpin [3 ]
Chang, Han [4 ,5 ]
机构
[1] Chung Shan Med Univ Hosp, Dept Surg, Taichung 40201, Taiwan
[2] Chung Shan Med Univ, Coll Med, Taichung 40201, Taiwan
[3] Natl Hlth Res Inst, Div Environm Hlth & Occupat Med, Zhunan, Taiwan
[4] China Med Univ, Dept Pathol, Coll Med, 91 Hsueh Shih Rd, Taichung 40402, Taiwan
[5] China Med Univ Hosp, Dept Pathol, Taichung, Taiwan
关键词
Heat-shock protein 90; non-small cell lung cancer; metastasis; survival; HSP90; INVASION; RESISTANCE; INHIBITORS; PROGNOSIS; THERAPY; STAGE;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: Heat-shock protein 90 (HSP90) is a molecular chaperone that stabilizes many client proteins in normal and cancer cells, and approximately 3% of intracellular HSP90 is located in the nucleus. HSP90 is also targeted for the treatment of advanced non-small cell lung cancer (NSCLC). This study aimed to elucidate the clinical role of nuclear HSP90 levels in tissues from patients with NSCLC. Materials and Methods: Nuclear and total HSP90 levels were assessed using immunohistochemistry. Results: Multivariate logistic regression showed that the total HSP90 level was independently positively associated with age (p=0.041) and tumor histology of squamous type (p=0.007). By contrast, nuclear HSP90 level was independently positively associated with higher performance score (p=0.011), ever-smoking history (p=0.006) and presence of lymph node (p=0.036) or distant (p<0.001) metastasis, but not age or tumor histology. The level of nuclear HSP90, but not total HSP90, was negatively correlated with patient survival time (p<0.001). Conclusion: Nuclear accumulation of HSP90 might be a predictor of metastasis and survival in patients with NSCLC.
引用
收藏
页码:2197 / 2203
页数:7
相关论文
共 28 条
  • [11] The Double-Edged Sword: Conserved Functions of Extracellular Hsp90 in Wound Healing and Cancer
    Hance, Michael W.
    Nolan, Krystal D.
    Isaacs, Jennifer S.
    [J]. CANCERS, 2014, 6 (02): : 1065 - 1097
  • [12] Holownia A, 2009, EUR J MED RES, V14, P104
  • [13] Mechanistic insights into acquired drug resistance in epidermal growth factor receptor mutation-targeted lung cancer therapy
    Ji, Hongbin
    [J]. CANCER SCIENCE, 2010, 101 (09): : 1933 - 1938
  • [14] A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
    Kamal, A
    Thao, L
    Sensintaffar, J
    Zhang, L
    Boehm, MF
    Fritz, LC
    Burrows, FJ
    [J]. NATURE, 2003, 425 (6956) : 407 - 410
  • [15] The molecular chaperone Hsp90 can negatively regulate the activity of a glucocorticosteroid-dependent promoter
    Kang, KI
    Meng, X
    Devin-Leclerc, J
    Bouhouche, I
    Chadli, A
    Cadepond, F
    Baulieu, EE
    Catelli, MG
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (04) : 1439 - 1444
  • [16] Koga F, 2009, ANTICANCER RES, V29, P797
  • [17] Liu W, 2014, AM J CANCER RES, V4, P256
  • [18] Recent advances in the development of mutant-selective EGFR inhibitors for non-small cell lung cancer patients with EGFR-TKI resistance
    Luo, Yung-Hung
    Chen, Yuh-Min
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2014, 3 (06) : 368 - 369
  • [19] Clinical factors and prognosis in non-small cell lung cancer
    Martins, SJ
    Pereira, JR
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1999, 22 (05): : 453 - 457
  • [20] Global cancer statistics, 2002
    Parkin, DM
    Bray, F
    Ferlay, J
    Pisani, P
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2005, 55 (02) : 74 - 108